42°21′48″N 71°05′28″W / 42.3633°N 71.091°W
 | |
 Moderna headquarters in Cambridge, Massachusetts | |
| Formerly | ModeRNA Therapeutics (2010–2018) |
|---|---|
| Company type | Public |
| |
| ISIN | US60770K1079 |
| Industry | Biotechnology |
| Founded | September 2010 |
| Founders | |
| Headquarters | 200 Technology Square Cambridge, Massachusetts, U.S. |
Key people |
|
| Products | |
| Revenue |  US$6.848 billion (2023) |
| US$−4.24 billion (2023) | |
| US$−4.71 billion (2023) | |
| Total assets | US$18.43 billion (2023) |
| Total equity | US$13.85 billion (2023) |
| Owners |
|
Number of employees | 5,600 (2023) |
| Website | modernatx |
| Footnotes / references [1][2][3] | |
Moderna, Inc. (/məˈdɜːrnə/ mə-DUR-nə)[4] is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response.[5][1] The company's name is derived from the terms "modified", "RNA", and "modern".[6][7][8]
The company's only commercial product is the Moderna COVID-19 vaccine, marketed as Spikevax. The company has 45 treatment and vaccine candidates, of which 38 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, respiratory syncytial virus, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines. The company's pipeline also includes a cell therapy-based treatment: a relaxin fusion protein being developed to treat acute decompensated heart failure. It also includes candidates that use OX40 ligand, interleukin 23, IL36G, and interleukin 12 for cancer immunotherapy, specifically treatment of breast cancer, urothelial carcinoma, lymphoma, and melanoma. Also being developed by Moderna is a regenerative medicine treatment that encodes vascular endothelial growth factor A to stimulate blood vessel growth for patients with myocardial ischemia.[1]
History
Moderna was founded in 2010 by Derrick Rossi, Timothy A. Springer, Kenneth R. Chien, Robert S. Langer, and Noubar Afeyan.[9] Stéphane Bancel, the current CEO, was appointed as CEO in 2011.[6][10] Between 2011 and 2017, Moderna raised $2 billion in venture capital funding.[7][8]
Product development
In 2013, the company formed a partnership with AstraZeneca to develop treatments for cardiovascular, metabolic, and renal diseases, as well as cancer. Moderna also was awarded a $25,000,000 grant by DARPA through a program Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious Threats (ADEPT-PROTECT).[11] Its stated goal was to develop an mRNA vaccine with the capability to suppress a global pandemic within 60 days. In January 2014, the company entered an agreement with Alexion Pharmaceuticals to develop treatments against ten diseases.[12] On January 14, 2014, Moderna announced the creation of its first venture, Onkaido Therapeutics, to focus "exclusively on developing mRNA-based oncology treatments."[13][14] It launched its second venture, Valera, in January 2015, with a focus on "viral, bacterial and parasitic infectious diseases."[15][16] Employees of Valera and Moderna developed an mRNA vaccine candidate against Zika virus infection.[17] Another venture, Elpidera, was announced in May 2015 to continue work on RNA therapies advancing Moderna's work with Alexion.[18][19]
In 2015, the company formed a partnership with Merck & Co. to develop treatments for cancer, and in 2016 the company formed a partnership with Vertex Pharmaceuticals to develop treatments for cystic fibrosis.[10][20][21][22] In January 2016, the Bill & Melinda Gates Foundation committed to provide at least $20 million in grant funding to the company.[1] In 2017, Alexion terminated its partnership with Moderna after safety issues prevented their work from reaching human trials.[23]
In July 2018, the company opened a 200,000 square foot facility in Norwood, Massachusetts for manufacturing, preclinical and clinical work.[24] In December 2018, Moderna became a public company via the largest initial public offering of a biotechnology company in history, raising $621 million by selling 27 million shares at $23 per share.[25][26]
The first mRNA vaccine developed by Moderna was for influenza in 2015, and its first antibody encoded by mRNA was in 2019.[6] In 2023, Moderna acquired OriCiro Genomics, a Japanese manufacturer of genetic engineering tools, in its first acquisition.[27]
In early 2023, the company in collaboration with Merck won breakthrough status from the FDA for its mRNA-4157/V940 drug candidate, a cancer vaccine.[28][29]
In July 2023, the company entered into an agreement with the Chinese government to develop mRNA drugs for exclusive use in China.[30]
COVID-19 vaccine
From 2020 to 2021, Moderna received $955 million from Operation Warp Speed to accelerate development of its COVID-19 vaccine, with $4.9 billion committed in total for producing 300 million vaccine doses.[31][32]
In March 2020, the Food and Drug Administration approved clinical trials for the Moderna COVID‑19 vaccine candidate, and in December, the vaccine, mRNA-1273, was issued an emergency use authorization in the United States.[33][34] In 2022, it gained FDA approval both for the monovalent vaccine, Spikevax, and a bivalent booster.[35]
In April 2022, Moderna announced plans to build a $180 million vaccine factory in Montreal, forming a 10-year partnership with the Government of Canada, Quebec, and McGill University to produce 100 million Spikevax doses annually and expand vaccine research capabilities.[36] The plant is scheduled to supply COVID-19 vaccines in the fall of 2025.[37]
In February 2023, the company agreed to pay $400 million to the National Institutes of Health, Dartmouth College, and Scripps Research to settle a dispute over the rights to a chemical technique that was used in the vaccine.[38]
In April 2023, a court affirmed a decision to cancel a patent by Arbutus Biopharma after a patent dispute with Moderna regarding its COVID-19 vaccine.[39]
Several legal cases between Moderna and Pfizer and BioNTech in various countries, alleging that the Pfizer–BioNTech COVID-19 vaccine violates the patent on Moderna's mRNA vaccine technology, are ongoing.[40]
Financial data
| Year | Revenue (mln. US$) | Net income (loss) (mln. US$) |
|---|---|---|
| 2019[1] | 60 | (514) |
| 2020[1] | 803 | (747) |
| 2021[1] | 18,471 | 12,202 |
| 2022[1] | 19,263 | 8,362 |
| 2023[1] | 6,848 | (4,710) |
See also
References
External links
- Official website
- Business data for Moderna, Inc.:
